All ozempic articles
-
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments